While it is not known if the low ANXA1 persists before stroke and can be linked to underlying conditions for stroke such as atherosclerosis, this finding suggest that plasma ANXA1 may predict clinical outcomes of AIS and the effectiveness of EVT therapies. This evidence concerns the gene ANXA1 and stroke disorder.